With nine other atypical antipsychotics already on the market (some of which are available as generics), did we really need another one? Given the pesky side effects of antipsychotics, maybe we did. Let’s take a look at what we know so far about Latuda (lurasidone) in an effort to figure out how to incorporate it into our clinical toolbox. Latuda was first approved by the US Food and Drug Administration (FDA) for use in schizophrenia in late 2010.

You can't view details of this content, please login or buy subscription here